Drug General Information (ID: DDIIEWO74Z)
  Drug Name Triamcinolone Drug Info Bumetanide Drug Info
  Drug Type Small molecule Small molecule
  Therapeutic Class Antiinflammatory Agents Diuretics
  Structure

 Mechanism of Triamcinolone-Bumetanide Interaction (Severity Level: Moderate)
     Increased risk of hypokalemia Click to Show/Hide Mechanism Graph
Could Not Find 2D Structure
      Drug Name Triamcinolone Bumetanide
      Mechanism Hypokalemia Hypokalemia
      Key Mechanism Factor 1
Factor Name Hypokalemia
Factor Description Hypokalemia is a condition in which the amount of potassium in your blood is lower than normal. If you are mildly hypokalemic, you may not have any signs or symptoms, but severe hypokalemia may have the following symptoms: fatigue, constipation, frequent or heavy urination, muscle cramps or skin tingling, muscle weakness, and a fast or irregular heartbeat.
      Mechanism Description
  • Increased risk of hypokalemia by the combination of Triamcinolone and Bumetanide 

Recommended Action
      Management Patients receiving potassium-depleting agents with corticosteroids should be monitored closely for development of hypokalemia, particularly if fludrocortisone or large doses of another corticosteroid or adrenocorticotropic agent is given. Potassium supplementation may be necessary. Patients should be advised to notify their physician if they experience signs of electrolyte disturbances such as weakness, lethargy, and muscle pains or cramps.

References
1 Chrousos GA, Kattah JC, Beck RW, Cleary PA "Side effects of glucocorticoid treatment. Experience of the Optic Neuritis Treatment Trial." JAMA 269 (1993): 2110-2. [PMID: 8468765]
2 Morris GC, Egan JG, Jones MK "Hypokalaemic paralysis induced by bolus prednisolone in Graves' disease." Aust N Z J Med 22 (1992): 312. [PMID: 1497563]
3 Powell JR "Steroid and hypokalemic myopathy after corticosteroids for ulcerative colitis. Systemic and tropical application." Am J Gastroenterol 52 (1969): 425-32. [PMID: 5346284]
4 Product Information. Hydeltrasol (prednisolone). Merck & Co, Inc, West Point, PA.
5 Ramsahoye BH, Davies SV, el-Gaylani N, Sandeman D, Scanlon MF "The mineralocorticoid effects of high dose hydrocortisone." BMJ 310 (1995): 656-7. [PMID: 7703757]
6 Seale JP, Compton MR "Side-effects of corticosteroid agents." Med J Aust 144 (1986): 139-42. [PMID: 3511355]
7 Thomas TP "The complications of systemic corticosteroid therapy in the elderly." Gerontology 30 (1984): 60-5. [PMID: 6698408]
8 Thorn GW "Clinical considerations in the use of corticosteroids." N Engl J Med 274 (1966): 775-81. [PMID: 17926885]